JP2024511163A5 - - Google Patents

Info

Publication number
JP2024511163A5
JP2024511163A5 JP2023558765A JP2023558765A JP2024511163A5 JP 2024511163 A5 JP2024511163 A5 JP 2024511163A5 JP 2023558765 A JP2023558765 A JP 2023558765A JP 2023558765 A JP2023558765 A JP 2023558765A JP 2024511163 A5 JP2024511163 A5 JP 2024511163A5
Authority
JP
Japan
Prior art keywords
amino acid
adenosine deaminase
modifications
group
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022050 external-priority patent/WO2022204574A1/en
Publication of JP2024511163A publication Critical patent/JP2024511163A/ja
Publication of JP2024511163A5 publication Critical patent/JP2024511163A5/ja
Pending legal-status Critical Current

Links

JP2023558765A 2021-03-26 2022-03-25 アデノシンデアミナーゼバリアント及びその使用 Pending JP2024511163A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166778P 2021-03-26 2021-03-26
US63/166,778 2021-03-26
US202163229057P 2021-08-03 2021-08-03
US63/229,057 2021-08-03
PCT/US2022/022050 WO2022204574A1 (en) 2021-03-26 2022-03-25 Adenosine deaminase variants and uses thereof

Publications (2)

Publication Number Publication Date
JP2024511163A JP2024511163A (ja) 2024-03-12
JP2024511163A5 true JP2024511163A5 (cg-RX-API-DMAC7.html) 2025-04-01

Family

ID=83397962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558765A Pending JP2024511163A (ja) 2021-03-26 2022-03-25 アデノシンデアミナーゼバリアント及びその使用

Country Status (8)

Country Link
US (1) US20240158775A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313118A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511163A (cg-RX-API-DMAC7.html)
KR (1) KR20240004276A (cg-RX-API-DMAC7.html)
AU (1) AU2022246176A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214494A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022204574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
EP4458963A1 (en) * 2023-05-04 2024-11-06 Technische Universität Dresden Highly active crispr base editors obtained through cas-assisted substrate-linked directed evolution (caslide)
WO2024227911A2 (en) * 2023-05-04 2024-11-07 Technische Universität Dresden Highly active crispr base editors obtained through cas-assisted substrate-linked directed evolution (caslide)
CN120290534A (zh) * 2024-01-10 2025-07-11 上海数因信科智能科技有限公司 腺嘌呤脱氨酶、包含其的碱基编辑器融合蛋白和碱基编辑器系统及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
AU2020216484A1 (en) * 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
JP7646552B2 (ja) * 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
AU2020322021A1 (en) * 2019-07-30 2022-02-10 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
US20220290121A1 (en) * 2019-08-30 2022-09-15 The General Hospital Corporation Combinatorial Adenine and Cytosine DNA Base Editors
AU2020344547A1 (en) * 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same

Similar Documents

Publication Publication Date Title
JP2025170240A5 (cg-RX-API-DMAC7.html)
US20230139474A1 (en) RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
CN113631708B (zh) 编辑rna的方法和组合物
JP2022546608A5 (cg-RX-API-DMAC7.html)
AU2019265019B2 (en) Methods of substituting pathogenic amino acids using programmable base editor systems
JP2024083479A (ja) エピゲノム編集のための組成物および方法
JP2022521460A5 (cg-RX-API-DMAC7.html)
JP2022519507A5 (cg-RX-API-DMAC7.html)
JP2025183226A5 (cg-RX-API-DMAC7.html)
EP4028026A1 (en) Novel nucleobase editors and methods of using same
CN105916983A (zh) 用于高效且特异性靶向包含高度重复基序的dna序列的稀有切割核酸内切酶的设计
JP2022545950A5 (cg-RX-API-DMAC7.html)
JP2024511131A5 (cg-RX-API-DMAC7.html)
JP2023545497A5 (cg-RX-API-DMAC7.html)
JP2024506375A5 (cg-RX-API-DMAC7.html)
JP2025505732A5 (cg-RX-API-DMAC7.html)
Myler et al. Structural organization of the maxicircle variable region of Trypanosoma brucei: identification of potential replication origins and topoisomerase II binding sites
RU2020114785A (ru) Искусственная модификация генома для регуляции экспрессии гена
JP2023515670A5 (cg-RX-API-DMAC7.html)
JP2021522825A5 (cg-RX-API-DMAC7.html)
CN109929865A (zh) 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用
JP2025514304A5 (cg-RX-API-DMAC7.html)
CN114599789A (zh) 人工合成mRNA及其利用
WO2025045078A1 (zh) 一种用于调控rna甲基化修饰的编辑系统及其应用
CN114144231A (zh) 用于治疗癌症的crispr方法